Prof Jake Shortt
Clinical (Professor)
The Sir Peter MacCallum Department of Oncology
261 Scholarly works
5 Projects
HIGHLIGHTS
2026
Journal article
POSTER: MDS-113: Updated Overall Survival and Long-Term Transfusion Independence From the Phase 3 COMMANDS Trial in Erythropoiesis-Stimulating Agent–Naïve Patients With Lower-Risk Myelodysplastic Syndromes
DOI: 10.1016/s2152-2650(26)00835-92026
Journal article
POSTER: TCL-416: Updated Clinical Data From the Phase 1/2 Study of Dibotatug (DR-01), a Non-Fucosylated Anti-CD94 Antibody, in Patients With Relapsed/Refractory Cytotoxic T/NK Cell Lymphomas
DOI: 10.1016/s2152-2650(26)01255-32026
Journal article
TCL-416: Updated Clinical Data From the Phase 1/2 Study of Dibotatug (DR-01), a Non-Fucosylated Anti-CD94 Antibody, in Patients With Relapsed/Refractory Cytotoxic T/NK Cell Lymphomas
DOI: 10.1016/s2152-2650(26)02792-82026
Journal article
MDS-113: Updated Overall Survival and Long-Term Transfusion Independence From the Phase 3 COMMANDS Trial in Erythropoiesis-Stimulating Agent–Naïve Patients With Lower-Risk Myelodysplastic Syndromes
DOI: 10.1016/s2152-2650(26)02210-x2026
Journal article
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study
DOI: 10.1182/bloodadvances.20250181412018
Research Grant
Targeting Transcriptional Addiction for Cancer Therapy.
2017
Research Grant
Exploiting and Defining the Immune Regulatory Activities of Bet Bromodomain Inhibitors
RECENT SCHOLARLY WORKS
2026
Journal article
The true cost of red cell transfusion for patients with myelodysplastic syndromes: A time-driven activity-based costing study
DOI: 10.1111/bjh.705562026
Journal article
Updated overall survival (OS) and long-term transfusion-independence (TI) from the phase 3 COMMANDS trial in erythropoiesis-stimulating agent (ESA)–naive patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS).
DOI: 10.1200/jco.2026.44.16_suppl.65662026
Journal article
Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia
DOI: 10.1182/bloodadvances.20250175752026
Journal article
Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
DOI: 10.1158/1535-7163.MCT-25-03062026
Journal article
The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia
DOI: 10.1111/bjh.70276
RECENT PROJECTS
2014
Research Grant
Awakening Dormant Genes to Help the Immune System Fight Blood Cancers
2015
Research Grant
Discovery of New Treatments for Therapy-Resistant Multiple Myeloma.
2015
Research Grant
Overcoming Resistance to Bromodomain Inhibition in Myc-Driven Lymphoma